US Army orders M1061 cartridges
Day and Zimmerman is to manufacture M1061 high-explosive cartridges for 60mm mortars, under a $92.7 million contract modification from the US Army.
Work will be performed in Parsons, Kansas, with an estimated completion date of 27 September 2021.
The M1061 was originally developed by Orbital ATK (now Northrop Grumman Innovation Systems), Saab Bofors Dynamics Switzerland, and the US Army Armament Research, Development and Engineering Center at the Picatinny Arsenal, New Jersey.
The cartridge was developed to increase the effectiveness of the 60mm mortar while improving its insensitive munitions characteristics. The increase in lethality (to near 81mm lethality) was accomplished by utilising a matrix comprised of pre-formed fragments and PBXN-110 explosive.
As part of our promise to deliver comprehensive coverage to our Defence Insight and Premium News subscribers, our curated defence news content provides the latest industry updates, contract awards and programme milestones.
More from Land Warfare
-
Drone wars: countries are looking for answers but do companies have the solutions?
Manufacturers are speeding up their counter-drone development efforts as countries increasingly focus on procurements to provide battlefield and national protection.
-
Fourth company looks to Texelis Celeris chassis to develop a new 4x4 vehicle
Finnish company SCATA will use the Texelis Celeris chassis for a new vehicle similar to the Serval 4x4 which Texelis is building with KNDS France for the French Army.
-
Thales Storm 2 counter-drone system being evaluated by potential customers
The attack drone threat from first-person view uncrewed aerial systems has been highlighted by recent conflicts and Thales has adapted its Storm 2 counter-improvised explosive device jammer to provide protection.
-
Rolls-Royce to lead powertrain development for MGCS in important step for the programme
The move signals significant progress for the delayed Franco-German Main Ground Combat System programme with first powerpack prototypes set to be tested before the end of the decade.